.ANALYSIS EMPHASIZE.16 Oct 2024.
In the NIAGARA trial, the addition of perioperative durvalumab to standard procedure for muscle-invasive sac cancer cells enhanced event-free as well as in general survival, denoting a brand new procedure choice for this health condition.